Huntingtin Aggregation Kinetics and Their Pathological Role in a Drosophila Huntington's Disease Model

被引:69
|
作者
Weiss, Kurt R. [1 ,2 ]
Kimura, Yoko [1 ,2 ,3 ]
Lee, Wyan-Ching Mimi [1 ,2 ]
Littleton, J. Troy [1 ,2 ]
机构
[1] MIT, Picower Inst Learning & Memory, Dept Biol, Cambridge, MA 02139 USA
[2] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA
[3] Tokyo Metropolitan Inst Med Sci, Lab Prot Metab, Setagaya Ku, Tokyo 1568506, Japan
关键词
NEURONAL INTRANUCLEAR INCLUSIONS; TRANSGENIC MOUSE MODEL; N-TERMINAL HUNTINGTIN; MUTANT HUNTINGTIN; AXONAL-TRANSPORT; CELL-DEATH; IN-VIVO; POLYGLUTAMINE DISEASE; TRINUCLEOTIDE REPEAT; CHAPERONES REDUCE;
D O I
10.1534/genetics.111.133710
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Huntington's disease is a neurodegenerative disorder resulting from expansion of a polyglutamine tract in the Huntingtin protein. Mutant Huntingtin forms intracellular aggregates within neurons, although it is unclear whether aggregates or more soluble forms of the protein represent the pathogenic species. To examine the link between aggregation and neurodegeneration, we generated Drosophila melanogaster transgenic strains expressing fluorescently tagged human huntingtin encoding pathogenic (Q138) or nonpathogenic (Q15) proteins, allowing in vivo imaging of Huntingtin expression and aggregation in live animals. Neuronal expression of pathogenic Huntingtin leads to pharate adult lethality, accompanied by formation of large aggregates within the cytoplasm of neuronal cell bodies and neurites. Live imaging and Fluorescence Recovery After Photobleaching (FRAP) analysis of pathogenic Huntingtin demonstrated that new aggregates can form in neurons within 12 hr, while preexisting aggregates rapidly accumulate new Huntingtin protein within minutes. To examine the role of aggregates in pathology, we conducted haplo-insufficiency suppressor screens for Huntingtin-Q138 aggregation or Huntingtin-Q138-induced lethality, using deficiencies covering similar to 80% of the Drosophila genome. We identified two classes of interacting suppressors in our screen: those that rescue viability while decreasing Huntingtin expression and aggregation and those that rescue viability without disrupting Huntingtin aggregation. The most robust suppressors reduced both soluble and aggregated Huntingtin levels, suggesting toxicity is likely to be associated with both forms of the mutant protein in Huntington's disease.
引用
收藏
页码:581 / U488
页数:25
相关论文
共 50 条
  • [41] QUANTIFYING MUTANT HUNTINGTIN IN HUNTINGTON'S DISEASE CSF
    Wild, Edward
    Robertson, Nicola
    Miller, James
    Traeger, Ulrike
    Haider, Salman
    Macdonald, Douglas
    Langbehn, Douglas
    Kuhn, Rainer
    Weiss, Andreas
    Tabrizi, Sarah
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (10):
  • [42] Huntingtin Aggregates in the Olfactory Bulb in Huntington's Disease
    Highet, Blake
    Dieriks, Birger Victor
    Murray, Helen C.
    Faull, Richard L. M.
    Curtis, Maurice A.
    FRONTIERS IN AGING NEUROSCIENCE, 2020, 12
  • [43] Huntington's disease: degradation of mutant huntingtin by autophagy
    Sarkar, Sovan
    Rubinsztein, David C.
    FEBS JOURNAL, 2008, 275 (17) : 4263 - 4270
  • [44] Osmolytes dynamically regulate mutant Huntingtin aggregation and CREB function in Huntington’s disease cell models
    Shreyaas Aravindan
    Samantha Chen
    Hannaan Choudhry
    Celine Molfetta
    Kuang Yu Chen
    Alice Y. C. Liu
    Scientific Reports, 10
  • [45] Osmolytes dynamically regulate mutant Huntingtin aggregation and CREB function in Huntington's disease cell models
    Aravindan, Shreyaas
    Chen, Samantha
    Choudhry, Hannaan
    Molfetta, Celine
    Chen, Kuang Yu
    Liu, Alice Y. C.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [46] A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease
    Goehler, H
    Lalowski, M
    Stelzl, U
    Waelter, S
    Stroedicke, M
    Worm, U
    Droege, A
    Lindenberg, KS
    Knoblich, M
    Haenig, C
    Herbst, M
    Suopanki, J
    Scherzinger, E
    Abraham, C
    Bauer, B
    Hasenbank, R
    Fritzsche, A
    Ludewig, AH
    Buessow, K
    Coleman, SH
    Gutekunst, CA
    Landwehrmeyer, BG
    Lehrach, H
    Wanker, EE
    MOLECULAR CELL, 2004, 15 (06) : 853 - 865
  • [47] Axonal transport defects in a drosophila model of Huntington's disease
    Littleton, JT
    Lee, WM
    JOURNAL OF NEUROCHEMISTRY, 2006, 96 : 143 - 143
  • [48] Altered lipid metabolism in Drosophila model of Huntington's disease
    Aditi, Kumari
    Shakarad, Mallikarjun N.
    Agrawal, Namita
    SCIENTIFIC REPORTS, 2016, 6
  • [49] Effect of luteolin on the transgenic Drosophila model of Huntington's disease
    Siddique, Yasir Hasan
    Rahul, Himanshi
    Varshney, Himanshi
    Mantasha, I
    Shahid, M.
    COMPUTATIONAL TOXICOLOGY, 2021, 17
  • [50] Altered lipid metabolism in Drosophila model of Huntington’s disease
    Kumari Aditi
    Mallikarjun N. Shakarad
    Namita Agrawal
    Scientific Reports, 6